Comparative Study of the Pharmacokinetics of Rinsulin® Mix 30/70, Suspension for Subcutaneous Administration, 100 IU / ml (OJSC GEROPHARM-Bio, Russia) and Humulin® M3, Suspension for Subcutaneous Administration, 100 IU / ml (Lilly France, France) Using the Euglycemic Hyperinsulinemic Clamp Method

Bioequivalence Clinical Trial

Official title:

Double-blinded, Randomized, Comparative, Crossover Study of the Pharmacokinetics of Rinsulin® Mix 30/70, Suspension for Subcutaneous Administration, 100 IU / ml (OJSC GEROPHARM-Bio, Russia) and Humulin® M3, Suspension for Subcutaneous Administration, 100 IU / ml (Lilly France, France) Using the Method of Euglycemic Hyperinsulinemic Clamp on Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04498884
• Other study ID #: RIN30-70-CL
• Status: Completed
• Phase: N/A
• Start date: July 18, 2017
• Est. completion date: October 24, 2017

Study information

• Verified date: July 2020
• Source: Geropharm
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Pharmacokinetics and pharmacodynamics study of 2 formulations of insulin mixtures Rinsulin® Mix 30/70, Suspension for Subcutaneous Administration, 100 IU / ml (OJSC GEROPHARM-Bio, Russia) versus Humulin® M3, Suspension for Subcutaneous Administration, 100 IU / ml (Lilly France, France).

Description:

Double-blinded, randomized, comparative, crossover study of comparative pharmacokinetics of Rinsulin® mix 30/70, suspension for subcutaneous administration, 100 IU / ml (OJSC GEROPHARM-Bio, Russia) and Humulin® M3, suspension for subcutaneous administration, 100 IU / ml (Lilly France, France) using hyperinsulinemic euglycemic clamp method on healthy volunteers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: October 24, 2017
• Est. primary completion date: October 24, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Signed informed consent to participate in the study.

• Men of the Caucasian race with a verified diagnosis "healthy" according to the data of standard clinical, laboratory and instrumental examination methods.

• Age 18-50, inclusive.

• Body mass index 18.5 - 27 kg / m2.

• Volunteers who have sexual contact with fertile women should agree to use barrier methods of contraception while participating in the study (unless they have undergone surgical sterilization). Study Participants must also not become a sperm donor within the specified period.

• Consent to all restrictions imposed during the study.

Exclusion Criteria:

• Acute inflammatory diseases within 3 weeks from the moment of complete recovery to the stage of screening.

• Presence in the family history of the closest relatives cases of verified diagnosis of diabetes mellitus of any type.

• Deviations from the norm of basic vital indicators (heart rate, blood pressure, respiratory rate, body temperature) and ECG from normal values and laboratory values from reference values during screening.

• Fasting plasma glucose> 6.1 mmol / L at screening.

• HbA1C> 6% at the time of screening.

• Oral glucose tolerance test - blood glucose level =7.8 mmol / L (2 hours after glucose loading) during screening.

• Hard-to-reach veins of the upper extremities, vein thrombosis, history of thrombophlebitis or family history of close relatives, "compromised" veins due to frequent preceding venipuncture.

• Taking medications, phytopreparations, biologically active additives within 14 days before screening.

• Significant blood loss 3 months before screening due to, for example, but not limited to the following points: a. donor blood donation; b. extended surgery or trauma leading to significant blood loss.

• Incomplete recovery from surgery or surgery scheduled while the volunteer is participating in the study.

• Mental, physical and other reasons interferes with adequately assessing behavior and correctly fulfill the conditions of the research protocol incl.:

1. A history of mental illness;

2. Current or history (three years before the first administration of the study drug) of narcotic, drug and / or substance abuse. A positive test for the content of drugs in urine during the screening period;

3. Anamnestic information about alcoholism or intake of more than 10 units. alcohol per week (1 unit of alcohol is equivalent to 0.5 liters of beer, 200 ml of dry wine or 50 ml of spirits). A positive test for alcohol in breath during the screening period;

4. Nicotine addiction (regular use of tobacco less than 6 months before screening).

• Any chronic diseases, incl. but not limited to positive test results for hepatitis C or hepatitis B, HIV, syphilis at the time of screening, Burdened allergological history.

• Presence of suspicion of an inflammatory disease of the urinary system based on the results of urinalysis during screening.

• Presence of oncological diseases within 5 years before the screening.

• History of organ transplantation (except of corneal transplant performed more than 3 months before the first injection of the study drug).

• Participation in a clinical trial of any drug or experimental medical device within 3 months prior to the first administration of the study drug.

• Any other condition that, in the reasonable opinion of the research physician, makes it difficult for the volunteer to participate in the study.

• History of hypersensitivity to heparin, insulin or any of the excipients of the investigational drugs.

Related Conditions & MeSH terms

• Bioequivalence

Intervention

Drug:
• Rinsulin® mix 30/70
one subcutaneous injection at a dose of 0.4 IU/kg
• Humulin® M3
one subcutaneous injection at a dose of 0.4 IU/kg

Locations

Country	Name	City	State
Russian Federation	"National Medical Research Center of Endocrinology" of the Ministry of Health of the Russian Federation	Moscow
Russian Federation	National Medical Research Center in name of V.A. Almazov " of the Ministry of Health of the Russian Federation	Saint-Petersburg
Russian Federation	LLC "BioEk", Russian Federation	St. Petersburg

Sponsors (1)

Lead Sponsor	Collaborator
Geropharm

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AUC 0-12	Total area under the curve "drug concentration - time" in the time interval from 0 to 12 h	-0.5 , 0, every 15 min till 6 h, every 30 min till 11h, every 60 min till 17h, every 120 min till 24h
Primary	Cmax	Test Drug Observed Maximum Plasma Concentration	-0.5 , 0, every 15 min till 6 h, every 30 min till 11h, every 60 min till 17h, every 120 min till 24h
Primary	GIR 0-12	Total area under the curve "glucose infusion rate - time" in the time interval from 0 to 12 h	1, -0.5, then every 5 min till 10 hour, every 10 min till 12 hour, every 15 min till 24 hour
Primary	GIR 0-24	Total area under the curve "glucose infusion rate - time" in the time interval from 0 to 24 h	1, -0.5, then every 5 min till 10 hour, every 10 min till 12 hour, every 15 min till 24 hour
Primary	GIR max	Maximum glucose infusion rate over the study period	1, -0.5, then every 5 min till 10 hour, every 10 min till 12 hour, every 15 min till 24 hour
Primary	tGIRmax	Time to reach maximum glucose infusion rate	1, -0.5, then every 5 min till 10 hour, every 10 min till 12 hour, every 15 min till 24 hour
Primary	TGIRlag	Time between the drug administration and the onset of action	1, -0.5, then every 5 min till 10 hour, every 10 min till 12 hour, every 15 min till 24 hour
Secondary	AUC 0-2	Total area under the curve "drug concentration - time" in the time interval from 0 to 2 h	-0.5 , 0, every 15 min till 6 h, every 30 min till 11h, every 60 min till 17h, every 120 min till 24h
Secondary	AUC 0-24	Total area under the curve "drug concentration - time" in the time interval from 0 to 24 h	-0.5 , 0, every 15 min till 6 h, every 30 min till 11h, every 60 min till 17h, every 120 min till 24h
Secondary	AUC 0-6	Total area under the curve "drug concentration - time" in the time interval from 0 to 6 h	-0.5 , 0, every 15 min till 6 h, every 30 min till 11h, every 60 min till 17h, every 120 min till 24h
Secondary	AUC 0-8	Total area under the curve "drug concentration - time" in the time interval from 0 h to 8	-0.5 , 0, every 15 min till 6 h, every 30 min till 11h, every 60 min till 17h, every 120 min till 24h
Secondary	mean residence time	average residence time of a drug molecule in the body	-0.5 , 0, every 15 min till 6 h, every 30 min till 11h, every 60 min till 17h, every 120 min till 24h
Secondary	kel	constant for drug elimination rate	-0.5 , 0, every 15 min till 6 h, every 30 min till 11h, every 60 min till 17h, every 120 min till 24h
Secondary	Tmax	Time to reach test drug Maximum Plasma Concentration	-0.5 , 0, every 15 min till 6 h, every 30 min till 11h, every 60 min till 17h, every 120 min till 24h
Secondary	t1/2	Half-life of a drug tested	-0.5 , 0, every 15 min till 6 h, every 30 min till 11h, every 60 min till 17h, every 120 min till 24h
Secondary	t50%-early	reaching 50% of the maximum insulin concentration before reaching Cmax	-0.5 , 0, every 15 min till 6 h, every 30 min till 11h, every 60 min till 17h, every 120 min till 24h
Secondary	t50%-late	reaching 50% of the maximum insulin concentration after reaching Cmax	-0.5 , 0, every 15 min till 6 h, every 30 min till 11h, every 60 min till 17h, every 120 min till 24h
Secondary	ratio ?max/AUC0-t	relative absorption rate	-0.5 , 0, every 15 min till 6 h, every 30 min till 11h, every 60 min till 17h, every 120 min till 24h